Your Article Summary
Merck warned by FDA over vaccine plant failings
Corporate News Releases - The Healthcare Sales & Marketing Network, 05/08/08
The agency said Merck had filed an 'inadequate response" to a Form 483 sent to the company several weeks ago, and it now needed to see immediate corrective action. The agency highlighted several areas in which the plant deviated from good manufacturing practices (GMP). For example, Merck is accused of not investigating why some batches of product were outside of specifications, as well as "failure to maintain production and process control," according to the FDA.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Mylan Receives Approval for Generic Version of Antiepileptic KeppraĆ 1000 mg
Mylan, 12/15/09
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09

See Latest Articles